1.Multimodal Interpretable Model for Predicting Pathological Complete Response After Neoadjuvant Therapy in Lung Cancer: a Multicenter Study
Qi LIU ; Junying LIU ; Pei ZHANG ; Ping WEI ; Yueping LIU
Medical Journal of Peking Union Medical College Hospital 2026;17(4):943-953
To develop an multimodal interpretable model that integrates whole slide images(WSI) and clinical features, and to validate its efficacy in predicting pathological complete response(pCR) in lung cancer patients following neoadjuvant therapy. The clinicopathologic data who received neoadjuvant therapy of patients as well as hematoxylin and eosin stained sections were retrospectively collected between March 2015 and March 2025. For the WSI branch, the predictive performance of five pathology foundation models(CTransPath, Virchow2, H-optimus-0, Phikon-Ⅴ2, and UNI-Ⅴ2) was compared within the CLAM-SB framework to identify the optimal feature extractor. The clinical branch was constructed using the extreme gradient boosting(XGBoost) model. Subsequently, a multimodal prediction model for pathologic complete response(MP-pCR) was established through decision-layer logistic regression fusion. Model performance was evaluated using the area under the receiver operating characteristic curve(AUC), accuracy, sensitivity, specificity, F1-score, and Brier score. Interpretability analysis was performed using attention heatmaps and the Shapley Additive Explanations(SHAP) algorithm. A total of 728 patients were enrolled in this study. Among them, a total of 676 patients from the Fourth Hospital of Hebei Medical University were selected as internal dataset, which was randomly divided into training set( MP-pCR model developed and validated based on multicenter data outperforms single-modality models in predicting pCR for lung cancer. The interpretability results demonstrate good consistency with clinicopathologic knowledge, suggesting that the model holds promise as a potential auxiliary reference for the clinical evaluation of treatment response and the optimization of individualized therapeutic decisions.
2.Construction of A Survival Prediction Model for Immunotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer Based on PD-L1 Expression Combined with Nutritional Status Score
Jinhua LI ; Ping QI ; Jili MA ; Yaxia LYU ; Caihong FU ; Longxia ZHANG ; Hui QIAO
Cancer Research on Prevention and Treatment 2026;53(6):457-466
Objective To analyze the factors affecting the prognosis of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) undergoing immunotherapy and construct an individualized prognostic nomogram prediction model. Methods A retrospective analysis was conducted on the clinical data of 385 patients with driver gene-negative, locally advanced or metastatic NSCLC who received first-line immune checkpoint inhibitors. Univariate and multivariate Cox regression analyses were used to identify prognostic risk factors, and a prognostic nomogram model was established. The predictive performance of the model was evaluated using the concordance index (C-index), time-dependent receiver operating characteristic (ROC) curves and area under the curve (AUC), and calibration curves. The cutoff value of the nomogram was calculated to stratify patients by risk. Survival curves were calculated by Kaplan-Meier analysis. Results Age (HR=1.775, 95%CI: 1.265-2.490), degree of differentiation (HR=0.365, 95%CI: 0.257-0.519), low PD-L1 expression (HR=0.661, 95%CI: 0.455-0.960), high PD-L1 expression (HR=0.423, 95%CI: 0.297-0.603), SCC-Ag (HR=1.549, 95%CI: 1.109-2.163), and CONUT score (HR=2.527, 95%CI: 1.797-3.554) were independent risk factors affecting overall survival (OS) of patients with NSCLC undergoing immunotherapy. The nomogram prediction model constructed on the basis of these factors had a C-index of 0.767. Time-dependent ROC curves for survival showed that the AUCs for 1-, 2-, and 3-year OS were 0.830, 0.853, and 0.886, respectively. Calibration curves indicated that the nomogram-predicted survival rates were in good agreement with the actual outcomes. The cutoff value for the study’s nomogram prediction model was 136.60 points, and survival curves showed statistically significant differences between different risk groups (P<0.05). Conclusion The nomogram model established in this study can effectively predict the prognosis of patients with driver gene-negative locally advanced or metastatic NSCLC treated with first-line immunosuppressive therapy. It provides a new tool for assessing prognosis and aids clinicians in formulating individualized treatment plans.
3.Clinical research progress of non-small cell lung cancer harboring EGFR gene exon 20 insertion mutation
Ping QI ; Xiaoming HOU ; Jinghua LI ; Dan DU ; Longxia ZHANG ; Hui QIAO
Tumor 2025;45(2):191-201
Epidermal growth factor receptor(EGFR)gene exon 20 insertion(ex20ins)mutation is a common driver gene activation mutation in non-small cell lung cancer(NSCLC).Tumors harboring this gene mutation are characterized by high heterogeneity,high malignancy,low detectability,poor response to conventional therapies,and poor prognosis.In recent years,significant progress has been made in the study of EGFR ex20ins mutation.The wide application of next-generation sequencing has improved the detection rate.The U.S.Food and Drug Administration(FDA)has approved the relevant indications of amivantamab in NSCLC patients with EGFR ex20ins mutation.A variety of new drugs have also achieved good results in previous studies.This article will summarize the structural characteristics,detection methods and clinical treatment progress of NSCLC patients with EGFR ex20ins mutations,hoping to provide help for the choice of clinical treatment for such patients.
5.Current status of the " Six-Good" Party branches for retired personnel in medical institutions and scientific research institutes
Qi JIN ; Yashuang BAI ; Yuheng CHEN ; Yan ZHOU ; Ping ZHANG ; Ximing DING
Chinese Journal of Hospital Administration 2025;41(7):524-530
Objective:To analyze the current status, identify existing issues, and explore countermeasures for the development of " Six-Good" retirement Party branches in medical institutions and scientific research institutes.Methods:In August 2024, ten medical and research institutions were selected. Focusing on the current status and existing issues in Party branch building for retired personnel, questionnaire surveys were conducted among staff members of the Party office and the retired cadres department, as well as retired Party members. Experts in the field of Party building were selected for semi-structured interviews. Core themes were then extracted through content analysis.Results:The questionnaire survey included a total of 399 survey respondents, comprising 112 staff members from the Party office and the retired cadres department, as well as 287 retired Party members. 212 (53.1%) of the respondents belonged to Party branches with over 50 members, 280 (70.2%) of the respondents expressed a preference for establishing Party branches based on similar business functions or former departments prior to retirement. 373 (93.5%) of the respondents believed Party branch committee members were adequately appointed. 33.7% (127/377) of the respondents perceived ideological fluctuations among retirement Party members. 175 (43.9%) of the respondents indicated that learning content was insufficiently diverse. Through interviews with 15 experts, it was found that the construction of retired party branches was faced with issues such as low participation in offline organizational life, insufficient effectiveness in the education and management of party members, limited role play of party members, and prominent service and support pressures. In response, the experts proposed specific suggestions such as innovating organizational forms, strengthening the effectiveness of education and management, and building platforms for role play.Conclusions:The " Six-Good" Party branch building for retired personnel of the medical and scientific research institutions had achieved certain results, but there were also some problems. It is necessary to further optimize organizational settings, strengthen the branch leadership, innovate learning forms, build a platform for role play, strictly implement various systems, and strengthen assistance to difficult party members.
6.Analysis of the core and bridge effects of interpersonal,relaxation and medication efficacy in self-management of rheumatoid arthritis patients
Yao DENG ; Sha ZHANG ; Xiaorun XIANG ; Ping WAN ; Qi REN ; Lei LIU
Journal of Army Medical University 2025;47(20):2532-2539
Objective To explore the networked association among the dimensions of self-efficacy in patients with rheumatoid arthritis(RA)and to identify core efficacy and bridge efficacy,and provide a basis for formulating precise nursing intervention strategies.Methods A total of 652 RA patients admitted in our hospital from September 2024 to January 2025 were enrolled with convenience sampling.The general information questionnaire and Rheumatoid Arthritis Self-Efficacy Scale(RASE)were used for assessment.Exploratory factor analysis was used to extract efficacy symptom clusters.With aid of R project,network analysis was employed to construct an association network among efficacy dimensions to calculate centrality indicators(strength,closeness,betweenness)to identify core efficacy and bridge efficacy.Results Exploratory factor analysis extracted 7 efficacy symptom clusters,with a cumulative variance contribution rate of 64.539%(P<0.001).Network analysis showed that the network density was 0.143,suggesting that there were moderate correlations among the self-efficacy dimensions."Relaxation efficacy 1(r1)"and"pain efficacy 1(a1)"had the strongest correlation(r=0.73).Interpersonal efficacy 2(i2)had the highest intensity centrality(6.88),and relaxation efficacy 3(r3)had the highest tightness(0.0125),and medication efficacy 1(m1)had the highest mediation(116),which were the core efficacy and bridge efficacy in this network group.Conclusion There are complex network-like correlations among the various dimensions of self-efficacy in RA patients.Interpersonal efficacy is the core driving factor,while relaxation and medication efficacies play the bridging role,jointly influencing the overall level of patients'self-management ability.
7.Effects of the prolyl hydroxylase 2 inhibitor cpd17 on mouse osteogenic precursor cells
Zhongqiu DU ; Xiaoyang QI ; Ping YANG ; Jianglin YU ; Yixin CHEN ; Linjian ZHANG ; Xusheng QIU
Chinese Journal of Tissue Engineering Research 2025;29(2):238-244
BACKGROUND:Prolyl hydroxylase domain 2(PHD2)inhibitors can regulate bone metabolism and relieve osteoporosis in ovariectomized rats.cpd17 is a small molecule oral PHD2 inhibitor newly developed by China Pharmaceutical University.It is effective in the treatment of renal anemia with few side effects,but its effect on bone formation and bone resorption is still unclear. OBJECTIVE:To investigate the effects of cpd17 on mouse osteogenic precursor cells. METHODS:Osteogenic precursor cells were treated with cpd17.Alkaline phosphatase activity and extracellular matrix mineralization were measured,and the expression levels of osteogenesis-and osteoclastogenesis-related markers,as well as PHD2 and hypoxia-inducible factor 1α,were detected.After inhibition of the hypoxia-inducible factor 1α pathway using LW6(a hypoxia-inducible factor 1α pathway inhibitor),alkaline phosphatase activity and extracellular matrix mineralization were detected again,as well as the expression levels of osteogenesis-and osteoclastogenesis-related markers,PHD2 and hypoxia-inducible factor 1α. RESULTS AND CONCLUSION:cpd17 significantly enhanced alkaline phosphatase activity and extracellular matrix mineralization,up-regulated the expression of osteogenesis-related markers,down-regulated the expression of osteoclastogenesis-related markers,up-regulated the expression of hypoxia-inducible factor 1α,down-regulate the expression of PHD2.However,cpd17's effects were significantly attenuated by LW6.To conclude,the PHD2 inhibitor cpd17 promotes osteogenic differentiation and inhibits osteoclastic differentiation through activation of the hypoxia-inducible factor 1α signaling pathway.
9.Explanation and interpretation of blood transfusion provisions for children with hematological diseases in the national health standard "Guideline for pediatric transfusion".
Ming-Yi ZHAO ; Rong HUANG ; Rong GUI ; Qing-Nan HE ; Ming-Yan HEI ; Xiao-Fan ZHU ; Jun LU ; Xiao-Jun XU ; Tian-Ming YUAN ; Rong ZHANG ; Xu WANG ; Jin-Ping LIU ; Jing WANG ; Zhi-Li SHAO ; Yong-Jian GUO ; Xin-Yin WU ; Jia-Rui CHEN ; Qi-Rong CHEN ; Jia GUO ; Ming-Hua YANG
Chinese Journal of Contemporary Pediatrics 2025;27(1):18-25
To guide clinical blood transfusion practices for pediatric patients, the National Health Commission has issued the health standard "Guideline for pediatric transfusion" (WS/T 795-2022). Blood transfusion is one of the most commonly used supportive treatments for children with hematological diseases. This guideline provides guidance and recommendations for blood transfusions in children with aplastic anemia, thalassemia, autoimmune hemolytic anemia, glucose-6-phosphate dehydrogenase deficiency, acute leukemia, myelodysplastic syndromes, immune thrombocytopenic purpura, and thrombotic thrombocytopenic purpura. This article presents the evidence and interpretation of the blood transfusion provisions for children with hematological diseases in the "Guideline for pediatric transfusion", aiming to assist in the understanding and implementing the blood transfusion section of this guideline.
Humans
;
Child
;
Hematologic Diseases/therapy*
;
Blood Transfusion/standards*
;
Practice Guidelines as Topic
10.Explanation and interpretation of the compilation of blood transfusion provisions for children undergoing hematopoietic stem cell transplantation in the national health standard "Guideline for pediatric transfusion".
Rong HUANG ; Qing-Nan HE ; Ming-Yan HEI ; Xiao-Fan ZHU ; Jun LU ; Xiao-Jun XU ; Tian-Ming YUAN ; Rong ZHANG ; Xu WANG ; Jin-Ping LIU ; Jing WANG ; Zhi-Li SHAO ; Ming-Yi ZHAO ; Yong-Jian GUO ; Xin-Yin WU ; Jia-Rui CHEN ; Qi-Rong CHEN ; Jia GUO ; Rong GUI ; Ming-Hua YANG
Chinese Journal of Contemporary Pediatrics 2025;27(2):139-143
To guide clinical blood transfusion practices for pediatric patients, the National Health Commission has issued the health standard "Guideline for pediatric transfusion" (WS/T 795-2022). Blood transfusion for children undergoing hematopoietic stem cell transplantation is highly complex and challenging. This guideline provides recommendations on transfusion thresholds and the selection of blood components for these children. This article presents the evidence and interpretation of the transfusion provisions for children undergoing hematopoietic stem cell transplantation, with the aim of enhancing the understanding and implementation of the "Guideline for pediatric transfusion".
Humans
;
Hematopoietic Stem Cell Transplantation
;
Child
;
Blood Transfusion/standards*
;
Practice Guidelines as Topic

Result Analysis
Print
Save
E-mail